Mounjaro and Zepbound still carry Lilly, but neuroscience sales rose 32% in the first half of 2026. Lilly reports third-quarter results on Oct. 29.
Recap by typeshit. Full story at TradingView.
Beauty companies are reportedly exploring products aimed at facial volume loss in people who have lost weight on GLP-1 drugs.
A short Fox16 social clip points to GLP-1 users shifting how they drink when they go out, with the full story linked in the station's bio.
A Facebook share points to shifting drinking habits in pubs and bars as more people take GLP-1 medications, with the full story linked.
Food Dive reports the Atkins brand is shifting its pitch toward lapsed GLP-1 users, a growing group food companies are now chasing.
Zhavoronkov quotes a speaker calling Mounjaro one of the best molecules humans have made, alongside Novo's semaglutide data at the aging conference.
STAT
STAT's Pharmalittle notes Catherine Hanaway says Lilly broke its promise on discounted drugs to hospitals, alongside new results for a Lilly weight loss drug.
Loading…